Tags

Type your tag names separated by a space and hit enter

Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Contraception. 1995 Mar; 51(3):149-53.C

Abstract

Our objective was to determine the effect of progestin-only contraceptives on metabolic parameters, bleeding patterns, and weight changes during the first year of use. Seventy-one women (> 95% Caucasian), who were advised regarding contraception alternatives, self-selected levonorgestrel implants (n = 44), depo-medroxyprogesterone acetate (n = 22), or oral norethindrone (n = 5). One year later, 11 levonorgestrel implant and five depomedroxyprogesterone acetate patients were randomly selected to compare (pre- and post-progestin use) levels of cholesterol, triglycerides, low density lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL), apolipoproteins A-1 and B-100, bilirubin, and sex hormone binding globulin. Monthly bleeding and spotting records were kept in each group. Body weights were also monitored in each group. No statistically significant differences in metabolic parameters were found between pre- and post-progestin use in the levonorgestrel implant and depo-medroxyprogesterone acetate groups. Continued bleeding patterns were more prominent in the levonorgestrel implant and oral norethindrone groups than in patients receiving depo-medroxyprogesterone acetate. No significant weight gain was detected in any group. No changes in metabolic parameters or weight were noted over the one year of use of levonorgestrel implants or depo-medroxyprogesterone acetate. Depo-medroxyprogesterone acetate had the highest incidence of amenorrhea.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City 84132, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7621683

Citation

Mainwaring, R, et al. "Metabolic Parameter, Bleeding, and Weight Changes in U.S. Women Using Progestin Only Contraceptives." Contraception, vol. 51, no. 3, 1995, pp. 149-53.
Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception. 1995;51(3):149-53.
Mainwaring, R., Hales, H. A., Stevenson, K., Hatasaka, H. H., Poulson, A. M., Jones, K. P., & Peterson, C. M. (1995). Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception, 51(3), 149-53.
Mainwaring R, et al. Metabolic Parameter, Bleeding, and Weight Changes in U.S. Women Using Progestin Only Contraceptives. Contraception. 1995;51(3):149-53. PubMed PMID: 7621683.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. AU - Mainwaring,R, AU - Hales,H A, AU - Stevenson,K, AU - Hatasaka,H H, AU - Poulson,A M, AU - Jones,K P, AU - Peterson,C M, PY - 1995/3/1/pubmed PY - 1995/3/1/medline PY - 1995/3/1/entrez KW - Americas KW - Biology KW - Bleeding KW - Body Weight--changes KW - Clinical Research KW - Contraception KW - Contraceptive Agents KW - Contraceptive Agents, Female KW - Contraceptive Agents, Progestin KW - Contraceptive Implants KW - Contraceptive Methods KW - Depo-provera KW - Developed Countries KW - Diseases KW - Family Planning KW - Levonorgestrel KW - Medroxyprogesterone Acetate KW - Menstruation Disorders KW - Metabolic Effects KW - Norethindrone KW - North America KW - Northern America KW - Oral Contraceptives KW - Physiology KW - Progestins, Low-dose KW - Research Report KW - Signs And Symptoms KW - United States KW - Utah SP - 149 EP - 53 JF - Contraception JO - Contraception VL - 51 IS - 3 N2 - Our objective was to determine the effect of progestin-only contraceptives on metabolic parameters, bleeding patterns, and weight changes during the first year of use. Seventy-one women (> 95% Caucasian), who were advised regarding contraception alternatives, self-selected levonorgestrel implants (n = 44), depo-medroxyprogesterone acetate (n = 22), or oral norethindrone (n = 5). One year later, 11 levonorgestrel implant and five depomedroxyprogesterone acetate patients were randomly selected to compare (pre- and post-progestin use) levels of cholesterol, triglycerides, low density lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL), apolipoproteins A-1 and B-100, bilirubin, and sex hormone binding globulin. Monthly bleeding and spotting records were kept in each group. Body weights were also monitored in each group. No statistically significant differences in metabolic parameters were found between pre- and post-progestin use in the levonorgestrel implant and depo-medroxyprogesterone acetate groups. Continued bleeding patterns were more prominent in the levonorgestrel implant and oral norethindrone groups than in patients receiving depo-medroxyprogesterone acetate. No significant weight gain was detected in any group. No changes in metabolic parameters or weight were noted over the one year of use of levonorgestrel implants or depo-medroxyprogesterone acetate. Depo-medroxyprogesterone acetate had the highest incidence of amenorrhea. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/7621683/Metabolic_parameter_bleeding_and_weight_changes_in_U_S__women_using_progestin_only_contraceptives_ L2 - https://linkinghub.elsevier.com/retrieve/pii/001078249500011X DB - PRIME DP - Unbound Medicine ER -